

- Adeno-associated virus 355
Adjuvant chemotherapy, upper urinary tract transitional cell carcinoma 22
Adrenal incidentaloma 173
Adrenalectomy 173
Age-standardized incidence rate, prostate cancer 311
Aggressive renal tumor 184
Aging male, erectile dysfunction 251
Androgen receptor antagonists 311
– suppression 135
Antibody basiliximab 232
- Balkan endemic nephropathy 240
Benign neoplasm 281
– prostatic hyperplasia 159, 327
Biochemical recurrence 122, 200
– – after radical prostatectomy 130
Bladder cancer 13, 69, 81, 152, 245, 255, 355
– –, environmental risk factors 152
– hyperactivity 57
– outlet obstruction 76
– rupture 92
– stones 284
– tissues, CD10 expression 107
– tumor progression/recurrence 27
Bladder-sparing surgery 18
Blocked urethral catheter 317
Body mass index 114
Bone metastases 50, 184
Botryoid-type tumor 89
Buccal mucosa 368
- Cambian layer 89
Camptothecin drug resistance 347
Catheterization complication 317
CD10 expression 107
Cerebral hypoperfusion, chronic 57
Chondrosarcoma 86
Chronic pelvic pain 227
– Prostatitis Symptom Index 227
Cisplatin 355
Complications 143
–, operative 216
C-reactive protein 127
Cryptorchidism 187, 264
Cystoprostatectomy 190
Cystoscopy 279
- Daily doses, LH-RH analogs/androgen receptor antagonists 311
Dermoid 279
– cyst 281
Diverticulum 368
Doppler sonography 170
Duplication of ureters 104
- Ectopic 118
Endourology 362
Enteral nutrition 139
Erectile dysfunction 182, 251
Erythropoietin 211
Extended release formulation 334
Extracellular matrix components 255
- Flank pain 286
Flow cytometry 275
Frozen section analysis 13
- Gene therapy 355
- Hand-assisted isthmectomy 94
HCl duloxetine 9
Hemorrhagic cystitis, morbidity 190
High-risk prostate cancer 122
Histopathological assessment 301
Horseshoe kidney 94
– – transplantation, long-term results 6
– –, surgical technique 6
Hydatid disease 371
Hypoxia-inducible factors (HIF-1 α , HIF-2 α) 255
- Ileal conduit 245
Imaging 69
Immunohistochemistry 76, 255
Immunological monitoring 232
Incidentally found adrenal tumors 173
Interleukin-2 receptor 232
Intracorporeal lithotripsy 284
Intravesical explosion 92
Ischemia, forebrain 57
- Kattan nomogram 222
Kidney calculi 340
– transplantation 6, 232
–, hydatidosis 371
- Knotting of tube 317
Krimpen study 159
- Laparoscopic left radical nephrectomy 94
Laparoscopy 118, 166, 190, 216
LH-RH analogs 311
Live-donor renal transplantation 42
Low-affinity nerve growth factor receptor 76
Lower urinary tract symptoms 251
Luteinizing hormone-releasing hormone agonist 135
Lymphoceles 42
- Magnetic resonance imaging 301
Malignant transformation 86
Medullary carcinoma 184
Metaplasia, children 46
Metastases 127
Metastasis, nodal 64
Munchausen syndrome 284
- Neoadjuvant hormonal therapy 122
Nephrectomy 118
Non-invasive urodynamics 159
– –, volunteer recruitment 159
Normal voiding pattern 322
- Operative failure 148
Overactive bladder 334
– –, treatment 327
- p53 355
– nuclear accumulation, transitional papillary bladder carcinoma 27
Paraurethral epidermoid cyst 187
Pelvic malignancy 18
Penile length 114
Percutaneous access point number and location 340
– nephrolithotomy 340
– –, complication rates 340
– –, success rates 340
Plasmakinetics 143
Pneumatic lithotripsy 148
Polymerase chain reaction 81
Positron emission tomography 69
Prazosin 269
Prescription practice, LH-RH analogs/androgen receptor antagonists 311

- Prevalence, overactive bladder 327
Priapism 182
Propiverine 334
Prostate 251
– cancer 50, 127, 135, 182, 200, 205, 211, 307, 311, 347
– – detection 301
– – status determination 307
– –, risk of recurrence 222
– growth, rats 269
Prostatectomy 130, 216, 222
Prostate-specific antigen 127, 130, 200
– – doubling time 205
– – level, elevated 222
Prostatic neoplasms 130, 216
Prostatitis 227
Protein profiling 347
Proteomics 347
Puberty 114
Pumpkin seed oil 269
Pyelolithotomy 118
Pyeloplasty 118
- Radical cystectomy 13
– –, recovery 139
– cystoprostatectomy 307
– nephrectomy 166
– nephroureterectomy/regional lymphadenectomy 22
– prostatectomy 9, 182, 200, 205, 211
Radionuclide treatment 50
Radiotherapy 190
Recruitment, epidemiological aspects 159
Renal abnormality 6
– artery 170
– cell carcinoma 94, 166
– contusion 362
– hemorrhage 34
– medullary carcinoma 184
– pelvis tumor 89
– transplantation 104
- Retroperitoneal/transperitoneal approach 166
Retropubic radical prostatectomy 301
Rhabdomyosarcoma 89
- Salvage radiotherapy 205
Salvia miltiorrhiza 275
Schiedam study 159
Selective embolization 362
Seminoma, testicular 64
Serum testosterone 135
Shock wave lithotripsy 179
Sickle cell trait 184
Sildenafil 170
Simple cyst vs. hydatid cyst 371
Single nucleotide polymorphism 81
Smoking 152
Solitary functioning kidneys 179
Spermatogenesis 275
Squamous metaplasia 46
Staging 69
Stent migration 297
Stents 42
Superselective catheterization 34
– embolization 34
- Ta-T1 transitional cell carcinoma 152
Teratoma 86, 279
Testicular cancer 86
– cystic lesion 281
– hypotrophy 114
– torsion 275
Testis, dermoid cyst 281
Testosterone 269
Thymidine phosphorylase 255
Total parenteral nutrition 139
Transient hypothyroidism 264
Transitional cell carcinoma 69
– – –, upper urinary tract 22
– papillary bladder carcinoma 27
Transureteroureterostomy 245
- Transurethral resection 216
– – of prostate 92, 143
- Undescended testes 264
Upper urothelial tumor 240
Ureteral herniation 286
– margin 13
Ureteric stent 297
– stenting, shock wave lithotripsy 179
Ureterocutaneostomy 245
Ureterolysis 286
Ureteroneocystostomy 42
Ureterscopy 148
Urethral polyp 187
Urethroplasty 368
Urge incontinence 327
Urinary bladder 46
– catheter 317
– continence 216
– diversion 245
– reconstruction 104
– tract infection 327
Urinoma 362
Urodynamics 9
Urokinase 81
Urolithiasis 284
Urological complications 42
– emergency 317
Urothelial bladder carcinomas 107
- Varicocele 114
Vascular endothelial growth factor 255
Ventral onlay 368
Verumontanum 187
Voiding diary 322
Volume-frequency chart 322